Tag: GlaxoSmithKline (GSK.NYSE)
-
Biohaven (BHVN.NYSE), Zosano Pharma (ZSAN.Q), Lundbeck (HLUYY.OTC) tackle a $41 billion problem that cruelly targets women
“More than 4 million adults experience chronic daily migraine – with at least 15 migraine days per month,” states The Migraine Research Foundation, “It affects 39 million people in the U.S. and 1 billion worldwide.”
-
Market Meltdown: gold & housing: “It’s not the pins – it’s the bubble”.
“It’s the financials that are really getting killed,” stated Schiff, “They have made all the loans that are not going to get repaid, so this is just like 2008, only it’s not just the banks that are going to need a bailout, it’s the hotels, it’s the airlines, it’s companies like Boeing, it’s the cruise…
-
DJIA plummets: divorce lawyers shudder as poor sexless couples grope each other in the night
“The National Marriage Project dubbed the drop in divorce ‘a silver lining’ to the Great Recession,” stated The L.A. Times, “arguing that tough times were pulling many husbands and wives closer together.”
-
Did Aytu BioScience (AYTU.Q) just SpankChain the NASDAQ?
When a sector gets hot, small cap stocks can often get a bump by sidling up to the hot sector with a new product/idea/opportunity. When the dust clears, the intrinsic value of the new offering is typically deemed to be low. We saw it in 3D-printing, with Dung Beetle Treats. We saw it in weed…
-
Moderna’s (MRNA.Q) “Coronavirus Vaccine” announcement – causes $3.4 billion jump in market cap
We’ll take a wild guess that precisely NONE of the retail investors who just drove up the price of the MRNA would recognise a “stabilized form of S protein” if they met it on a beach, made sand castles with it – then took it home to play Spin-The-Bottle.
-
vTv Therapeutics (VTVT.Q) surges 55% on type 1 diabetes drug trial
“A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes,” stated clinical researcher Dr. John Buse.
-
Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.